Olland Anne, Falcoz Pierre-Emmanuel, Massard Gilbert
Lung Transplantation Group, University Hospital Strasbourg, Strasbourg, France.
INSERM (French institute for health and medical research) 1260 Regenerative Nanomedecine, Translational Medicine Federation of Strasbourg, University of Strasbourg, Strasbourg, France.
J Thorac Dis. 2018 May;10(5):3132-3140. doi: 10.21037/jtd.2018.05.34.
Lung transplantation has become an efficient life-saving treatment for patients with end stage respiratory disease. The increasing good outcome following lung transplantation may be explained by growing experience of transplant teams and availability of potent immunosuppressive drugs. Nevertheless, the latter carries an inherent risk for malignancy besides other common side effects such as systemic hypertension, diabetes and renal dysfunction. Malignancies occur in a smaller proportion of patients but explain for a large proportion of deaths following transplantation. From the first year post-transplantation they will represent the third cause of death with an increasing incidence along post lung transplant survival. In this chapter, we will browse the different types of malignancies arising following lung transplantation. According to the different techniques for lung transplantation, specific types of bronchogenic carcinoma will be described in the explanted lung, in the native lung, and in the graft. Risk factors associated to immunosuppressive therapy, but also to occupational and environmental factors, especially smoking, will be discussed. Eventually, we will strive at integrating recommendations for the treatment of malignancies following lung transplantation.
肺移植已成为终末期呼吸系统疾病患者一种有效的挽救生命的治疗方法。肺移植后越来越好的治疗效果或许可以通过移植团队经验的增加以及强效免疫抑制药物的可获得性来解释。然而,后者除了会带来全身性高血压、糖尿病和肾功能不全等其他常见副作用外,还存在发生恶性肿瘤的内在风险。恶性肿瘤在较小比例的患者中发生,但在移植后死亡原因中占很大比例。从移植后的第一年起,它们将成为第三大死因,并且随着肺移植后存活时间的延长,其发病率不断上升。在本章中,我们将浏览肺移植后出现的不同类型的恶性肿瘤。根据肺移植的不同技术,将描述在切除的肺、原生肺和移植肺中发生的特定类型的支气管源性癌。将讨论与免疫抑制治疗相关的危险因素,以及职业和环境因素,尤其是吸烟。最后,我们将努力整合肺移植后恶性肿瘤的治疗建议。